AliSB, GurnariC. Allogenic hematopoietic stem cell transplantation in VEXAS: A review of 33 patients. Clin Rheumatol, 2024; 43(11):3565-3575; doi: 10.1007/s10067-024-07160-7
2.
BeckDB, BodianDL, ShahV, et al.Estimated prevalence and clinical manifestations of UBA1 variants associated with VEXAS syndrome in a clinical population. JAMA, 2023; 329(4):318-324; doi: 10.1001/jama.2022.24836
3.
BeckDB, FerradaMA, SikoraKA, et al.Somatic mutations in UBA1 and severe adult-onset autoinflammatory disease. N Engl J Med, 2020; 383(27):2628-2638; doi: 10.1056/NEJMoa2026834
4.
BourbonE, HeibligM, Gerfaud ValentinM, et al.Therapeutic options in VEXAS syndrome: Insights from a retrospective series. Blood, 2021; 137(26):3682-3684; doi: 10.1182/blood.2020010177
5.
CollinsJC, BalandaN, MagazinerSJ, et al.Novel disease-causing mutations in UBA1 reveal disease mechanisms in bone marrow failure and inflammation. Blood, 2022; 140(Supplement 1):2914-2915; doi: 10.1182/blood-2022-168031
6.
D’AngeloG. Hematopoietic cells vacuolation, not always a reactive event. The VEXAS syndrome. Int J Lab Hematol, 2023; 45(1):e15-e16; doi: 10.1111/ijlh.13955
7.
FaurelA, HeibligM, KosmiderO, et al.Recurrent mutations of the active adenylation domain of UBA1 in atypical form of VEXAS syndrome. Hemasphere, 2023; 7(4):e868; doi: 10.1097/HS9.0000000000000868
8.
FerradaMA, SikoraKA, LuoY, et al.Somatic mutations in UBA1 define a distinct subset of relapsing polychondritis patients with VEXAS. Arthritis Rheumatol, 2021; 73(10):1886-1895.
9.
Georgin-LavialleS, TerrierB, GuedonAF, et al.; GFEV, GFM, CEREMAIA, MINHEMON. Further characterization of clinical and laboratory features in VEXAS syndrome: Large-scale analysis of a multicenter case series of 116 French patients. Br J Dermatol, 2022; 186(3):564-574; doi: 10.1111/bjd.20805
GurnariC, MannionP, PanditI, et al.UBA1 screening in sweet syndrome with hematological neoplasms reveals a novel association between VEXAS and chronic myelomonocytic leukemia. Hemasphere, 2022; 6(10):e775; doi: 10.1097/HS9.0000000000000775
12.
Gutierrez-RodriguesF, KusneY, FernandezJ, et al.Spectrum of clonal hematopoiesis in VEXAS syndrome. Blood, 2023; 142(3):244-259; doi: 10.1182/blood.2022018774
13.
HeibligM, FerradaMA, KosterMJ, et al.Ruxolitinib is more effective than other JAK inhibitors to treat VEXAS syndrome: A Retrospective Multicenter Study. Blood, 2022; 140(8):927-931; doi: 10.1182/blood.2022016642
14.
KhitriMY, HadjadjJ, MekinianA, et al.VEXAS syndrome: An update. Joint Bone Spine, 2024; 91(4):105700; doi: 10.1016/j.jbspin.2024.105700
15.
LacombeV, HadjadjJ, Georgin-LavialleS, et al.Vacuoles in bone marrow progenitors: VEXAS syndrome and beyond. Lancet Haematol, 2024; 11(2):e160-e167; doi: 10.1016/S2352-3026(23)00375-7
16.
Loeza-UribeMP, Hinojosa-AzaolaA, Sánchez-HernándezBE, et al.VEXAS syndrome: Clinical manifestations, diagnosis, and treatment. Reumatol Clin (Engl Ed), 2024; 20(1):47-56; doi: 10.1016/j.reumae.2023.12.004
17.
MobiniM, ShekarrizR, Ali Mohammad PourR, et al.Inflammatory rheumatologic disorders in patients with myelodysplastic syndromes: A cross-sectional study. Int J Hematol Oncol Stem Cell Res, 2015; 9(1):22-25.
18.
MoudryP, LukasC, MacurekL, et al.Ubiquitin-activating enzyme UBA1 is required for cellular response to DNA damage. Cell Cycle, 2012; 11(8):1573-1582; doi: 10.4161/cc.19978
19.
ObiorahIE, PatelBA, GroarkeEM, et al.Benign and malignant hematologic manifestations in patients with VEXAS syndrome due to somatic mutations in UBA1. Blood Adv, 2021; 5(16):3203-3215; doi: 10.1182/bloodadvances.2021004976
20.
OoTM, KoayJTJ, LeeSF, et al.Thrombosis in VEXAS syndrome. J Thromb Thrombolysis, 2022; 53(4):965-970; doi: 10.1007/s11239-021-02608-y
21.
PoulterJA, CollinsJC, CargoC, et al.Novel somatic mutations in UBA1 as a cause of VEXAS syndrome. Blood, 2021; 137(26):3676-3681; doi: 10.1182/blood.2020010286
22.
RaaijmakersMHGP, HermansM, AalbersA, et al.Azacytidine treatment for VEXAS syndrome. Hemasphere, 2021; 5(12):e661; doi: 10.1097/HS9.0000000000000661
23.
SirenkoM, BernardE, CreignouM, et al.Molecular and clinical presentation of UBA1-mutated myelodysplastic syndromes. Blood, 2024; 144(11):1221-1229; doi: 10.1182/blood.2023023723
24.
StubbinsRJ, McGinnisE, JohalB, et al.VEXAS syndrome in a female patient with constitutional 45,X (Turner syndrome). Haematologica, 2022; 107(4):1011-1013; doi: 10.3324/haematol.2021.280238
25.
UchinoK, KanasugiJ, EnomotoM, et al.VEXAS syndrome. Int J Hematol, 2022; 116(4):463-464; doi: 10.1007/s12185-022-03448-z
26.
van der MadeCI, PotjewijdJ, HoogstinsA, et al.Adult-onset autoinflammation caused by somatic mutations in UBA1: A Dutch case series of patients with VEXAS. J Allergy Clin Immunol, 2022; 149(1):432-439.e4; doi: 10.1016/j.jaci.2021.05.014
27.
VergneaultH, PicardC, Georgin-LavialleS. Break down the barriers of auto-inflammation: How to deal with a monogenic auto-inflammatory disease and immuno-hematological features in 2022? Immunology, 2023; 168(1):1-17; doi: 10.1111/imm.13579
28.
VitaleA, CaggianoV, Della CasaF, et al.Development and implementation of the AIDA international registry for patients with VEXAS syndrome. Front Med (Lausanne), 2022; 9:926500; doi: 10.3389/fmed.2022.926500
